Lupin launches Mycophenolate Mofetil Tablets USP

Lupin Limited (Lupin), global pharmaceutical company, announced today the launch of Mycophenolate Mofetil Tablets USP, 500 mg, after Lupin's alliance partner Concord Biotech Limited (Concord) received an approval for its ANDA from the United States Food and Drug Administration.

Mycophenolate Mofetil Tablets USP, 500 mg, are the generic equivalent of CellCept® Tablets of Roche Palo Alto LLC, indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants.

Mycophenolate Mofetil Tablets USP (RLD: CellCept®) had an annual sales of approximately USD 87 million in the U.S. (IQVIA MAT October 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.981.85 as compared to the previous close of Rs. 976.15. The total number of shares traded during the day was 127420 in over 3558 trades.

The stock hit an intraday high of Rs. 989 and intraday low of 975.25. The net turnover during the day was Rs. 125184192.

Source : Equity Bulls

Keywords